2019 American Transplant Congress
Effect of Induction Therapy on Outcomes of De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from the TRANSFORM Study
1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland
*Purpose: To assess the effect of induction therapy on efficacy and safety outcomes of de novo renal transplant recipients (RTxR) receiving everolimus with reduced calcineurin…2019 American Transplant Congress
Improving the Organ Donation Process: Updated
Northwell Health, New Hyde Park, NY
*Purpose: Due to the complexity of care that each ICU patient requires, the bedside nurse may miss the clinical trigger that would indicate an appropriate…2019 American Transplant Congress
The Effect of a Novel Dosing Protocol for the De Novo Use of LCP Tacrolimus in Kidney Transplant Recipients Managed on a Steroid-Free Maintenance Immunosuppression Regimen
*Purpose: It is not known if an extended release formulation of tacrolimus (LCPT, Envarsus XR®) can be successfully dosed to achieve an early therapeutic trough…2019 American Transplant Congress
Incidence of Cytomegalovirus in Moderate Risk Kidney Transplant Recipients Receiving Low Dose Valganciclovir
*Purpose: Studies evaluating the efficacy of valganciclovir (VGC) at 450 mg daily versus 900 mg daily for the prevention of cytomegalovirus (CMV) in kidney transplant…2019 American Transplant Congress
Implementation of Novel Machine-Learning Techniques to Tailor Donornet® Organ Offers to Center and Surgeon Preference
Transplant Center, Massachusetts General Hospital, Boston, MA
*Purpose: Real-time communication regarding organ placement is critical. For this purpose, UNOS launched DonorNet®, a computerized allocation algorithm, to aid and facilitate organ placement. However,…2019 American Transplant Congress
“Desens Light”: Single Center Experience Using Rituximab for High Immunologic Risk Kidney Transplant Recipients with Historic DSA
Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL
*Purpose: To evaluate the effectiveness of rituximab as induction therapy for pts undergoing kidney transplant (Tx) with historic DSA (hDSA) [Desens. Light].*Methods: 104 consecutive pts…2019 American Transplant Congress
Blood Group Incompatible Living Donor Kidney Transplantation in Patients with End-Stage Kidney Disease Due to Diabetes Kidney Disease
*Purpose: Diabetes is a growing public health problem, and diabetes kidney disease (DKD) is the most prevalent chronic kidney disease and the major cause of…2018 American Transplant Congress
CTLA4-Ig and Bortezomib Successfully Reverses Established DSA Responses in Allograft-Sensitized Recipients
Background: Sensitized recipients have lower rates of transplantation and poorer outcomes. We and others have reported that the delayed administration of CTLA4-Ig can disrupt fully-established…2018 American Transplant Congress
Primary Oral Vancomycin Prophylaxis Reduces the Incidence of Clostridium difficile Infection among Lung Transplant Recipients
Cleveland Clinic Foundation, Cleveland, OH.
Purpose: To determine the efficacy of primary oral vancomycin prophylaxis in reducing the incidence of Clostridium difficile infection (CDI) in the early post-op period among…2018 American Transplant Congress
Donor Derived Transmissions in 2016-2017: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC)
DTAC, United Network for Organ Sharing, Richmond, VA.
The DTAC evaluates unanticipated potential donor-derived transmission events (PDDTE), including mostly infections (I) & malignancies (M), to assess for likelihood of donor transmission. Reporting policy…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 14
- Next Page »